retatrutide dosing schedule clinical trial A Clinician's Guide to Retatrutide Dosage for Weight Loss

doi: 10.1001/jamasurg.2016.4610

We present this article in accordance with the Narrative Review reporting checklist (available at Methods A search of the literature was conducted on OVID (1947May 2025) using the terms [papilledema OR intracranial hypertension OR idiopathic intracranial hypertension OR brain pseudotumor] AND [glucagon like peptide 1 OR glucagon like peptide 1 receptor agonist OR semaglutide OR exendin 4 OR liraglutide OR tirzepatide]

Medical Disclaimer: The information provided in this article is for educational purposes only

The new approval for Retevmo, which was previously authorized to treat patients 12 and older with RET-positive thyroid cancers, is based on a single-arm study that showed an overall response rate of 48%, with a median duration of response not reached after 12 months of follow-up